DOI: 10.12890/2026_006332
Acquired thrombotic thrombocytopenic purpura with a poor response to treatment can be an initial manifestation of occult signet ring cell carcinoma and other malignancies
Authors
mohammadahmad20023@gmail.com
Keywords
Microangiopathic hemolytic anemia, thrombotic thrombocytopenic purpura, thrombotic microangiopathy, ADAMTS13Abstract
Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a severe microangiopathic hemolytic anemia (MAHA) characterized by profound ADAMTS13 deficiency. MAHA can also manifest as a paraneoplastic syndrome, particularly in advanced malignancies, with cancer-associated MAHA (CA-MAHA) linked to signet ring cell carcinoma being exceptionally rare.
Case description: We present the case of a 42-year-old Arab male who initially presented with classic features of aTTP, including severe MAHA, profound thrombocytopenia, and renal and neurological dysfunction, confirmed by an ADAMTS13 activity level of 6%. Despite standard TTP therapy including plasma exchange, his atypical response and rapid deterioration prompted further investigation, leading to the diagnosis of aggressive, metastatic signet ring cell carcinoma. Tragically, he passed away less than a week after first presentation.
Conclusion: This case underscores the critical importance of maintaining a high index of suspicion for occult malignancies in patients with atypical thrombotic microangiopathy presentations, especially those with an incomplete response to conventional TTP therapies. It emphasizes the need for comprehensive diagnostic workup and a multidisciplinary approach to manage these complex and often fatal conditions, as early identification of underlying cancer is crucial for guiding appropriate, often tumour-directed, therapy and improving patient outcomes.
References
- Martinez J. Microangiopathic hemolytic anemia. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. Hematology. 4th ed. New York: McGraw-Hill; 1995. p. 657.
- Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ 2017;189:E153-E159. doi: 10.1503/cmaj.160142
- Eisa N, Nasef K, Emarah Z, Fattah MMA, Shamaa S. A Metastatic Signet Ring Cell Carcinoma Presented as Acquired Thrombotic Thrombocytopenic Purpura: A Case Report. J Hematol 2018;7:72-75. doi: 10.14740/jh386e
- Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Br J Haematol 2012;158:323-335. doi: 10.1111/j.1365-2141.2012.09167.x
- Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) 1979;58:377-384. doi: 10.1097/00005792-197909000-00004
- Abdel Samie A, Sandritter B, Theilmann L. Severe microangiopathic hemolytic anemia as first manifestation of a CUP syndrome. Rapid hematologic remission under polychemotherapy. Med Klin (Munich) 2004;99:148-153. German. doi: 10.1007/s00063-004-1023-8
- Scully M. Cancer and Thrombotic Microangiopathy. JOP 2026:12;531-532. doi :10.1200/JOP.2016.012708
- Morton JM, George JN. Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. J Oncol Pract 2016;12:523-530. doi: 10.1200/JOP.2016.012096
- Fontana S, Gerritsen HE, Kremer Hovinga J, Furlan M, Lämmle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol 2001;113:100-102. doi: 10.1046/j.1365-2141.2001.02704.x
- Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist 2007;12:11-19. doi: 10.1634/theoncologist.12-1-11
